FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Schneebaum Marc R 		2. Issuer Name and Ticker or Trading Symbol

SYNTA PHARMACEUTICALS CORP [ MDGL ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
SVP and CFO
(Last)          (First)          (Middle)

C/O MADRIGAL PHARMACEUTICALS, INC., 500 OFFICE CENTER DRIVE, SUITE 400 		3. Date of Earliest Transaction (MM/DD/YYYY)

7/22/2016
(Street)

FORT WASHINGTON, PA 19034
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   7/22/2016     A    25714   (1) (2) A $0   27856   (2) D    
Common Stock   7/22/2016     F    8548   (3) D $9.48   19308   (2) D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
( 1)  Represents the vesting and settlement of restricted stock units ("RSUs") upon the completion of the Issuer's merger transaction with Madrigal Pharmaceuticals, Inc. on July 22, 2016.
( 2)  Reflects a 1-for-35 reverse stock split that was effected by the Issuer on July 22, 2016.
( 3)  Shares withheld by the Registrant to satisfy minimum statutory withholding requirements upon vesting of RSUs. Withheld shares were not sold.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Schneebaum Marc R
C/O MADRIGAL PHARMACEUTICALS, INC.
500 OFFICE CENTER DRIVE, SUITE 400
FORT WASHINGTON, PA 19034

SVP and CFO

Signatures
/s/ Garrett Winslow, Attorney-in-Fact 7/22/2016
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Synta Pharmaceuticals Corp. (MM) (NASDAQ:SNTA)
過去 株価チャート
から 10 2024 まで 11 2024 Synta Pharmaceuticals Corp. (MM)のチャートをもっと見るにはこちらをクリック
Synta Pharmaceuticals Corp. (MM) (NASDAQ:SNTA)
過去 株価チャート
から 11 2023 まで 11 2024 Synta Pharmaceuticals Corp. (MM)のチャートをもっと見るにはこちらをクリック